Membrane transport and antitumor activity of pirarubicin, and comparison with those of doxorubicin

Japanese Journal of Cancer Research

Volumn 90, Issue 7, 1999, Pages 775-780

  Sugiyama, Tomomi ^a   Sadzuka, Yasuyuki ^a   Nagasawa, Kazuki ^b   Ohnishi, Noriaki ^b   Yokoyama, Teruyoshi ^b   Sonobe, Takashi ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Cancer chemotherapy; Doxorubicin; Nuclear uptake; Pirarubicin; Theanine

Indexed keywords

DOXORUBICIN; DRUG; PIRARUBICIN; THEANINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL LEVEL; CELL MEMBRANE TRANSPORT; CELL NUCLEUS MEMBRANE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG UPTAKE; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MEMBRANE TRANSPORT; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SARCOMA; TUMOR VOLUME;

EID: 0032773405     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00814.x     Document Type: Article

References (19)

1. Goren, D., Gabizon, A. and Barenholz, Y. The influence of physical characteristics of liposomes containing doxorubicin on their pharmacological behavior. Biochim. Biophts. Acta, 1029, 285-294 (1990).
2. Sadzuka, Y., Nakai, S., Miyagishima, A., Nozawa, Y. and Hirota, S. The effect of dose on the distribution of adriamycin encapsulated in polyethyleneglycol-coated liposomes. J. Drug Target., 3, 31-37 (1995).
3. Sadzuka, Y., Hirotsu, S., Miyagishima, A., Nozawa, Y. and Hirota, S. The study of polyethyleneglycol-coated liposomes containing CPT-11. J. Liposome Res., 7, 241-260 (1997).
4. Hamada, H. and Tsuruo, T. Functional role for 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc. Natl. Acad. Sci. USA, 83, 7785-7789 (1986).
5. Simon, S. M. and Schindlert, M. Cell biological mechanisms of multidrug resistance in tumors. Proc. Natl. Acad. Sci. USA, 91, 3497-3504 (1994).
6. Nagasawa, K., Natazuka, T., Nomiyama, M., Ohnishi, N. and Yokoyama, T. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of daunorubicin and doxorubicin in HL60 and its resistant cells and comparison with those of pirarubicin. Biol. Pharm. Bull., 19, 100-105 (1996).
7. Nagasawa, K., Natazuka, T., Chihara, K., Kitazawa, F., Tsumura, A., Takara, K., Nomiyama, M., Ohnishi, N. and Yokoyama, T. Transport mechanism of anthracycline derivatives in human leukemia cell lines: uptake and efflux of pirarubicin in HL60 and pirarubicin-resistant HL60 cells. Cancer Chemother. Phamacol., 37, 297-304 (1996).
8. Nagasawa, K., Ohnishi, N. and Yokoyama, T. Transport mechanisms of idarubicin, an anthracycline derivative, in human leukemia HL60 cells and mononuclear cells, and comparison with those of its analogs. Jpn. J. Cancer Res., 88, 750-759 (1997).
9. Nagasawa, K., Ohnishi, N. and Yokoyama, T. Possibility of contribution of nucleoside transport system to pirarubicin uptake by HL60 cells but not mononuclear cells. Jpn. J. Cancer Res., 89, 673-680 (1998).
10. Talmadge, J. E., Key, M. E. and Hart, I. R. Characterization of a murine ovarian reticulum cell sarcoma of histiocytic origin. Cancer Res., 41, 1271-1280 (1981).
11. Talmadge, J. E. and Hart, I. R. Morphologic studies on a murine reticulum cell sarcoma (histiocytic sarcoma) of histiocytic origin and its metastasis. Vet. Pathol., 20, 342-352 (1983).
12. Hart, I. R., Talmadge, J. E. and Fidler, I. J. Metastatic behavior of a murine reticulum cell sarcoma exhibiting organ-specific growth. Cancer Res., 41, 1281-1287 (1981).
13. Sugiyama, T. and Sadzuka, Y. Enhancing effects of green tea components on the antitumor activity of adriamycin against M5076 ovarian sarcoma. Cancer Lett., 133, 19-26 (1998).
14. Tsuruo, T., Iida, H., Tsukagoshi, S. and Sakurai, Y. 4′-O-Tetrahydropyranyladriamycin as a potential new antitumor agent. Cancer Res., 42, 1462-1467 (1982).
15. Sadzuka, Y., Sugiyama, T., Miyagishima, A., Nozawa, Y. and Hirota, S. The effects of theanine, as a novel biochemical modulator, on the antitumor activity of adriamycin. Cancer Lett., 105, 203-209 (1996).
16. Sadzuka, Y., Sugiyama, T. and Hirota, S. Modulation of cancer chemotherapy by green tea. Clin. Cancer Res., 4, 153-156 (1998).
17. Graham, H. N. Green tea composition, consumption, and polyphenol chemistry. Prev. Med., 21, 334-350 (1992).
18. Kunimoto, S., Miura, K., Takahashi, Y., Takeuchi, T. and Umezawa, H. Rapid uptake by cultured tumor cells and intracellular behavior of 4′-O-tetrahydropypanyladriamycin. J. Antibiot., 36, 312-317 (1983).
19. Pieters, R., Huismans, D. R., Loonen, A. H., Hahlen, K., Berg, A. van der Dose-van den, Wering, E. R. and Veerman, A. J. P. Relation of cellular drug resistance to long term clinical outcome in childhood acute lymphoblastic leukemia. Lancet, 338, 399 (1991).